22157.jpg
Global Idiopathic Pulmonary Fibrosis Disease Treatment Markets, 2018-2019 & 2020-2024
September 08, 2021 03:58 ET | Research and Markets
Dublin, Sept. 08, 2021 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets" report has been added to ResearchAndMarkets.com's offering.The current report...
Logo.png
Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space
August 17, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space  The Idiopathic Pulmonary...
22157.jpg
Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Report 2021 with 10-Year Disease Incidence and Prevalence Forecasts
July 13, 2021 05:13 ET | Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
May 11, 2021 07:01 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
TreviLogo.png
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
March 25, 2021 16:05 ET | Trevi Therapeutics
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW...
TreviLogo.png
Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 16:05 ET | Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Algernon Logo 1.png
Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
August 25, 2020 08:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
August 05, 2020 08:37 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia
July 07, 2020 08:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
cohbar.JPG
CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis
December 16, 2019 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...